Oliver Van Oekelen

10PUBLICATIONS
44CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer geneticsPredictive and prognostic markersGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 20, 2025
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy.

Adolfo Aleman, Oliver Van Oekelen, David T Melnekoff

|Sep 24, 2024
Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria.

Sara Zhukovsky, Joshua White, Rajshekhar Chakraborty

|Sep 16, 2024
Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.

Santiago Thibaud, Ryan L Subaran, Scott Newman

|Nov 15, 2022
Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020.

Oliver Van Oekelen, Nicole Birrer, William Wesson

|Nov 03, 2022
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.

Oliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine

|Aug 26, 2022
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.

Tarek H Mouhieddine, Oliver Van Oekelen, David T Melnekoff

Pageof 2

Frequent Collaborators

4 joint publications

Tarek H Mouhieddine

3 joint publications

Hearn Jay Cho

3 joint publications

Santiago Thibaud

3 joint publications

Sundar Jagannath